Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeted therapies: bevacizumab--has it reached its final resting place?

Literature DB >> 21386819

Targeted therapies: bevacizumab--has it reached its final resting place?

David J Kerr¹, Annie M Young.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2011 PMID： 21386819 DOI： 10.1038/nrclinonc.2011.32

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

× No keyword cloud information.

8 in total

Review 1. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors: R K Jain
Journal: Nat Med Date: 2001-09 Impact factor: 53.440

2. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery.

Authors: W Cacheux; T Boisserie; L Staudacher; O Vignaux; B Dousset; O Soubrane; B Terris; C Mateus; S Chaussade; F Goldwasser
Journal: Ann Oncol Date: 2008-08-05 Impact factor: 32.976

3. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

Authors: Michael R Mancuso; Rachel Davis; Scott M Norberg; Shaun O'Brien; Barbara Sennino; Tsutomu Nakahara; Virginia J Yao; Tetsuichiro Inai; Peter Brooks; Bruce Freimark; David R Shalinsky; Dana D Hu-Lowe; Donald M McDonald
Journal: J Clin Invest Date: 2006-10 Impact factor: 14.808

Review 4. Biomarkers to predict the clinical efficacy of bevacizumab in cancer.

Authors: Adrian M Jubb; Adrian L Harris
Journal: Lancet Oncol Date: 2010-12 Impact factor: 41.316

5. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

Authors: Carmen J Allegra; Greg Yothers; Michael J O'Connell; Saima Sharif; Nicholas J Petrelli; Linda H Colangelo; James N Atkins; Thomas E Seay; Louis Fehrenbacher; Richard M Goldberg; Seamus O'Reilly; Luis Chu; Catherine A Azar; Samia Lopa; Norman Wolmark
Journal: J Clin Oncol Date: 2010-10-12 Impact factor: 44.544

6. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors: Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal: J Clin Oncol Date: 2008-04-20 Impact factor: 44.544

7. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245

8. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.

Authors: Lei Xu; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Daniel C Chung; Gregory Y Lauwers; Rekha Samuel; Paul Shellito; Brian G Czito; Pei-Chun Lin; Martin Poleski; Rex Bentley; Jeffrey W Clark; Christopher G Willett; Rakesh K Jain
Journal: Cancer Res Date: 2009-10-13 Impact factor: 12.701

8 in total

6 in total

Targeted therapies: bevacizumab--has it reached its final resting place?

Review 1. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

2. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery.

3. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

Review 4. Biomarkers to predict the clinical efficacy of bevacizumab in cancer.

5. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

6. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

7. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

8. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.

1. Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?

Review 2. Reappraising antiangiogenic therapy for breast cancer.

Review 3. Therapeutic antibodies against cancer.

Review 4. Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?

Review 5. The measurement and modification of hypoxia in colorectal cancer: overlooked but not forgotten.

Review 6. The notch ligand JAGGED1 as a target for anti-tumor therapy.